Pharma Conversations Podcast

In this episode of Pharma Conversations, we sit down with Melanie Adams, Associate Director, Knowledge Management at MSD, to unpack what knowledge management really is and how it can be embedded into everyday ways of working.

Melanie shares practical strategies for capturing tacit knowledge (including the ROCK tool), accelerating speed to competency, and supporting regulatory readiness. Melanie also discusses the role of AI, digital tools, and communities of practice in breaking silos across global sites.

Contact us at: [email protected]

This episode is sponsored by STERIS.

In this episode, Jim Polarine from STERIS breaks down how Annex 1 is reshaping contamination control strategy world wide covering CCS design, risk‑based decision making, residue management, gowning, environmental monitoring, and material transfer pitfalls like cart wheels. He contrasts Europe and the US, explores the challenges of ageing facilities and new technologies.

Contact us at: [email protected]

This episode is sponsored by STERIS.

In this episode of Pharma Conversations, Laura Brennan Director of Technical Consulting at Ecolab breaks down the science and regulation behind disinfectant rotation in pharma cleanrooms, from the EU GMP Annex 1 and the FDA expectations to what actually works in practice.

She shares new multi-site data on rotation strategies, how to use risk-based EM trends, when to escalate to VHP, and why hands-on training matters more than SOPs alone. 

Contact us at: [email protected]

This episode is sponsored by Ecolab.

In this episode, Rory Mullen, Head of Biopharma and Food at IDA Ireland, discusses how Ireland has evolved into a leading hub for pharmaceutical and biopharmaceutical manufacturing.

He explores where the strongest growth is occurring from biologics and ADCs to GLP-1 weight-loss treatments and explains why global companies continue to invest in high-value operations in Ireland. He also highlights the role of AI, sustainability, and skilled talent in maintaining the country’s position at the forefront of the industry.

Contact us at: [email protected]

This episode is sponsored by Ecolab.

In this episode of Pharma Conversations Podcast, Kevin O’Donnell (HPRA) explains how QRM needs to move beyond tick‑box exercises to become truly knowledge‑driven and evidence‑based.

He walks through the main changes in ICH Q9(R1) and what regulators expect from companies in practice. We discuss culture, misuse of RPNs and the idea of a “living” QRM system under continuous improvement.

Kevin also shares how these principles apply to emerging areas like ATMPs, digitalisation and AI.

Contact us at: [email protected]

This episode is sponsored by Ecolab.

In this episode of Pharma Conversations, we’re joined by Patrick Nieuwenhuizen, a global leader in pharmaceutical quality, compliance, and sterility assurance with more than 30 years of experience across sterile manufacturing, biologics, and advanced therapies.

Together, we explore the realities of unannounced FDA inspections, the shift toward permanent inspection readiness, and the cultural, operational, and knowledge‑management foundations needed to withstand modern regulatory scrutiny.

Contact us at: [email protected]

This episode is sponsored by Ecolab.

In this episode of Pharma Conversations, we’re joined by Kevin O’Donnell, Market Compliance Manager and Senior GMP Inspector at the HPRA, to discuss what good inspection readiness looks like from a regulator’s perspective.

Kevin shares common inspection gaps, how organisations can build continuous readiness, and insights on data integrity, people preparedness, and outsourced activities. He also reflects on his experience working in Japan, exploring its culture of quality and lessons for the Irish and European pharma industry.

Contact us at: [email protected]

This episode is sponsored by Ecolab.

Matt Moran breaks down the challenges shaping the pharmaceutical industry from supply‑chain fragility and increasing regulatory complexity to the urgent need for sustainability and skilled talent. He highlights why the industry must modernise manufacturing, embrace digitalisation, and build greater resilience to stay competitive in a rapidly shifting global landscape.

Matt is a prominent Irish biopharmaceutical industry expert, consultant, and former Director of BioPharmaChem Ireland (part of IBEC), where he spent three decades shaping Ireland's reputation as a global life sciences hub. He is currently an independent consultant, a board member of industry groups, and acts as a judge for industry awards. He is also Chair of the ARC Hub for Therapeutics Governance Committee. 

Contact us at: [email protected]

This episode is sponsored by Ecolab.